Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A health ministry panel of experts on July 31 endorsed the plan for Daiichi Sankyo Co. to begin producing and distributing the vaccine, which creates immunity for the conventional strain of the virus.

Back in 2011, the world held its breath after the Fukushima Daiichi nuclear plant in Japan suffered a failure of its cooling ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Tokyo Electric Power Company announced it has successfully completed the trial removal of a sample of fuel debris from the primary containment vessel of unit 2 at the damaged Fukushima Daiichi nuclear ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

TOKYO (AP) — A remote-controlled robot has safely returned with a tiny piece of melted fuel it collected from inside one of three damaged reactors at the tsunami-hit Fukushima Daiichi nuclear ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...